|
1
|
Gatti L, Cossa G, Tinelli S, Carenini N,
Arrighetti N, Pennati M, Cominetti D, De Cesare M, Zunino F,
Zaffaroni N and Perego P: Improved apoptotic cell death in
drug-resistant non-small-cell lung cancer cells by tumor necrosis
factor-related apoptosis-inducing ligand-based treatment. J
Pharmacol Exp Ther. 348:360–371. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Janssen-Heijnen ML, van Steenbergen LN,
Steyerberg E, Visser O, De Ruysscher DK and Groen HJ: Long-term
excess mortality for survivors of non-small cell lung cancer in the
Netherlands. J Thorac Oncol. 7:496–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chung JH, Choi YS, Cho JH, Kim HK, Kim J,
Zo JI and Shim YM: Uniportal video-assisted thoracoscopic
lobectomy: An alternative to conventional thoracoscopic lobectomy
in lung cancer surgery? Interact Cardiovasc Thorac Surg.
20:813–819. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tacelli N, Santangelo T, Scherpereel A,
Duhamel A, Deken V, Klotz E, Cortot A, Lafitte JJ, Wallyn F, Remy J
and Remy-Jardin M: Perfusion CT allows prediction of therapy
response in non-small cell lung cancer treated with conventional
and anti-angiogenic chemotherapy. Eur Radiol. 23:2127–2136. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takenaka T, Takenoyama M, Inamasu E,
Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M,
Seto T and Ichinose Y: Role of surgical resection for patients with
limited disease-small cell lung cancer. Lung Cancer. 88:52–56.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Donington JS, Koo CW and Ballas MS: Novel
therapies for non-small cell lung cancer. J Thorac Imaging.
26:175–185. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Takahashi Y, Yamaoka K, Nishikawa M and
Takakura Y: Quantitative and temporal analysis of gene silencing in
tumor cells induced by small interfering RNA or short hairpin RNA
expressed from plasmid vectors. J Pharm Sci. 98:74–80. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gazzaniga P, Gradilone A, Giuliani L,
Gandini O, Silvestri I, Nofroni I, Saccani G, Frati L and Aglianò
AM: Expression and prognostic significance of LIVIN, SURVIVIN and
other apoptosis-related genes in the progression of superficial
bladder cancer. Ann Oncol. 14:85–90. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
LaCasse EC, Mahoney DJ, Cheung HH,
Plenchette S, Baird S and Korneluk RG: IAP-targeted therapies for
cancer. Oncogene. 27:6252–6275. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Guan HP, Sun JZ, Feng XL, Chen JS, Chen
FJ, Cheng XF, Liu XW and Ni B: Effects of RNA interference-mediated
knockdown of livin and survivin using monomethoxypolyethylene
glycol-chitosan nanoparticles in MG-63 osteosarcoma cells. Mol Med
Rep. 13:1821–1826. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang AQ, Wang PJ, Huang T, Zhou WL and
Landman J: Effects of monomethoxypolyethylene glycol-chitosan
nanoparticle-mediated dual silencing of livin and survivin genes in
prostate cancer PC-3M cells. Genet Mol Res. 5:2016.doi:
10.4238/gmr.15027430.
|
|
12
|
Yang D, Song X, Zhang J, Ye L, Wang S, Che
X, Wang J, Zhang Z, Wang L and Shi W: Therapeutic potential of
siRNA-mediated combined knockdown of the IAP genes (Livin, XIAP,
and Survivin) on human bladder cancer T24 cells. Acta Biochim
Biophys Sin (Shanghai). 42:137–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Huang H, Zhou H, Du T, Zeng L,
Cao Y, Chen J, Lai Y, Li J, Wang G and Guo Z: Activation of nuclear
factor kB pathway and downstream targets survivin and livin by
SHARPIN contributes to the progression and metastasis of prostate
cancer. Cancer. 120:3208–3218. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
McIntyre GJ and Fanning GC: Design and
cloning strategies for constructing shRNA expression vectors. BMC
Biotechnol. 6:12006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao X, Yuan Y, Zhang Z, Feng X, Zhang J,
Yuan X and Li J: Effects of shRNA-silenced livin and survivin on
lung cancer cell proliferation and apoptosis. J BUON. 19:757–762.
2014.PubMed/NCBI
|
|
16
|
Xu W, Chang H, Qin CK and Zhai YP: Impact
of Co-transfection with livin and survivin shRNA expression vectors
on biological behavior of HepG2 cells. Asian Pac J Cancer Prev.
14:5467–5472. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kong X, Li L, Sun L, Fu K, Long J, Weng X,
Ye X, Liu X, Wang B, Yan S, et al: Rapid diagnosis of aneuploidy
using segmental duplication quantitative fluorescent PCR. PLoS One.
9:e889322014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mavridis K, Stravodimos K and Scorilas A:
Downregulation and prognostic performance of microRNA 224
expression in prostate cancer. Clin Chem. 59:261–269. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tirrò E, Consoli ML, Massimino M, Manzella
L, Frasca F, Sciacca L, Vicari L, Stassi G, Messina L, Messina A
and Vigneri P: Altered expression of c-IAP1, survivin, and Smac
contributes to chemotherapy resistance in thyroid cancer cells.
Cancer Res. 66:4263–4272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Spänkuch B, Matthess Y, Knecht R, Zimmer
B, Kaufmann M and Strebhardt K: Cancer inhibition in nude mice
after systemic application of U6 promoter-driven short hairpin RNAs
against PLK1. J Natl Cancer Inst. 96:862–872. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Custodio A, Méndez M and Provencio M:
Targeted therapies for advanced non-small-cell lung cancer: Current
status and future implications. Cancer Treat Rev. 38:36–53. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van der Drift MA, Karim-Kos HE, Siesling
S, Groen HJ, Wouters MW, Coebergh JW, de Vries E and
Janssen-Heijnen ML: Progress in standard of care therapy and modest
survival benefits in the treatment of non-small cell lung cancer
patients in the Netherlands in the last 20 years. J Thorac Oncol.
7:291–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mansoori B, Shotorbani S Sandoghchian and
Baradaran B: RNA interference and its role in cancer therapy. Adv
Pharm Bull. 4:313–321. 2014.PubMed/NCBI
|
